Last updated: 18 July 2019 at 8:14pm EST

Venture Management Co. V, L... Net Worth




The estimated Net Worth of Venture Management Co. V, L... is at least $28.5 Million dollars as of 5 February 2014. Venture L owns over 472,405 units of Trevena Inc stock worth over $28,549,498 and over the last 11 years Venture sold TRVN stock worth over $0.

Venture L TRVN stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 472,405 units of TRVN stock worth $3,306,835 on 5 February 2014.

The largest trade Venture's ever made was buying 472,405 units of Trevena Inc stock on 5 February 2014 worth over $3,306,835. On average, Venture trades about 472,405 units every 0 days since 2014. As of 5 February 2014 Venture still owns at least 3,811,682 units of Trevena Inc stock.

You can see the complete history of Venture L stock trades at the bottom of the page.



Insiders trading at Trevena Inc

Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, and Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.



What does Trevena Inc do?

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.



What does Trevena Inc's logo look like?

Trevena Inc logo

Complete history of Venture L stock trades at Trevena Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
5 Feb 2014 Venture Management Co. V, L...
Buy 472,405 $7.00 $3,306,835
5 Feb 2014
3,811,682


Trevena Inc executives and stock owners

Trevena Inc executives and other stock owners filed with the SEC include: